You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,278,061


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,278,061
Title:Polymorphisms in the EGFR pathway as markers for cancer treatment
Abstract: The invention provides compositions and methods for identifying patients for single agent anti-EGFR therapy. The methods comprise determining the genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive response. Patients identified as responsive are then treated with the appropriate therapy.
Inventor(s): Lenz; Heinz-Josef (Los Angeles, CA), Zhang; Wu (Los Angeles, CA)
Assignee: University of Southern California (Los Angeles, CA)
Application Number:12/523,517
Patent Claims:1. A method for determining whether a human colorectal cancer patient is likely or less likely responsive to a single agent anti-EGFR antibody based therapy selected from Cetuximab or an antibody that binds to the same epitope that Cetuximab binds, comprising screening a suitable cell or tissue sample isolated from said patient for the genetic polymorphism of COX-2 T8473C SNP wherein the presence of the genetic polymorphism of (C/C) for COX-2 T8473C SNP indicates the patient is likely responsive to said single agent anti-EGFR antibody based therapy and wherein the absence of the genetic polymorphism of (C/C) for COX-2 T8473C SNP indicates the patient is less likely responsive to said single agent anti-EGFR antibody based therapy.

2. The method of claim 1, wherein the colorectal cancer is a metastatic or non-metastatic cancer selected from the group consisting of rectal cancer, colorectal cancer, and colon cancer.

3. The method of claim 1, wherein the patient is suffering from metastatic colorectal cancer.

4. The method of claim 1, wherein the presence of the genetic polymorphism of (C/C) for COX-2 T8473C SNP indicates the patient is likely responsive to said single agent anti-EGFR antibody based therapy.

5. The method of claim 1, wherein the absence of the genetic polymorphism of (C/C) for COX-2 T8473C SNP indicates the patient is less likely responsive to said single agent anti-EGFR antibody based therapy.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.